CD19 and acute lymphoblastic leukemia: The approval for market of blinatumomab, a bispecific CD3/CD19 T-cell engager, and tisagenlecleucel, a CAR T cell therapy, has demonstrated dramatic progress in the treatment of pediatric R/R B-cell precursor ALL (R/R BCP ALL).